Expression of the apoptotic markers in normal breast epithelium, benign mammary dysplasia and in breast cancer

• Autorzy: Koda M , Kanczuga-Koda L. , Reszec J. , Sulkowska M. , Famulski W. , Baltaziak M. , Kisielewski W. , Sulkowski S.
• Języki publikacji: EN

Abstrakty

EN

Apoptosis and proliferation are processes associated with the development and progression of breast cancer. The sensitivity of tumour cells to the induction of apoptosis depends on the balance between pro- and anti-apoptotic proteins. The expression of Bak and Bcl-2 was examined using an immunohistochemical method in 71 primary breast cancers. Furthermore, Bcl-2 and Bak were assessed in the normal mammary gland as well as in benign mammary dysplasia adjacent to breast cancer. Positive immunostaining for Bcl-2 was observed in 77.8% of cases of normal breast epithelium (NBE), 93% of benign dysplasia without intraductal proliferation (BBD) as well as in 94% of intraductal proliferative lesions of the breast (BIPL). Expression of Bak was detected in 39% of cases of NBE, 45% of BBD and in 67% of BIPL. In breast cancer Bcl-2 and Bak expression was found in 83% and 70% of the cases studied, respectively. Increased Bcl-2 expression in primary tumours significantly correlated with favourable prognostic factors, namely pT1, G2 and lack of metastases to the regional lymph nodes (p < 0.01, p < 0.03, p < 0.02, respectively). There were no relationships between Bak and the clinicopathological features studied, but our results indicate changes in the expression of Bak during breast cancer development and progression. It would appear to be important to assess and compare pro- and anti-apoptotic proteins between normal mammary gland, benign mammary dysplasia and the primary tumours of breast cancer. This knowledge should be helpful in understanding breast cancer development and progression.

Słowa kluczowe

EN

normal mammary gland; apoptotic marker; normal breast epithelium; breast; benign mammary dysplasia; mammary gland; expression; cancer

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2004
• Tom: 63
• Numer: 3
• Opis fizyczny: p.337-341,ref.

Twórcy

autor

Koda M

• Medical University of Bialystok, Waszyngtona 13, 15-269 Bialystok, Poland

autor

Kanczuga-Koda L.

autor

Reszec J.

autor

Sulkowska M.

autor

Famulski W.

autor

Baltaziak M.

autor

Kisielewski W.

autor

Sulkowski S.

Bibliografia

• 1. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dorken B (1995) Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer, 60: 854–859.
• 2. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC (1998) Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer, 82: 1296–1302.
• 3. Borner C (1996) Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem, 271: 12695–12698.
• 4. Furth PA, Bar-Peled U, Li M, Lewis A, Laucirica R, Jager R, Weiher H, Russell RG (1999) Loss of antimitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model. Oncogene, 18: 6589–6596.
• 5. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI (1994) Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer, 59: 619–628.
• 6. Heermeier K, Benedict M, Li M, Furth P, Nunez G, Hennighausen L (1996) Bax and Bcl-xs are induced at the onset of apoptosis in involuting mammary epithelial cells. Mech Dev, 56: 197–207.
• 7. Humphreys RC (1999) Programmed cell death in the terminal endbud. J Mammary Gland Biol Neoplasia, 4: 213–220.
• 8. Humphreys RC, Krajewska M, Krnacik S, Jaeger R, Weiher H, Krajewski S, Reed JC, Rosen JM (1996) Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Development, 122: 4013–4022.
• 9. Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC, Agnantis NJ (2000) Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Anticancer Res, 20: 4221–4225.
• 10. Jacotot E, Costantini P, Laboureau E, Zamzami N, Susin SA, Kroemer G (1999) Mitochondrial membrane permeabilization during the apoptotic process. Ann NY Acad Sci, 887: 18–30.
• 11. Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol, 145: 1191–1198.
• 12. Koda M, Sulkowski S, Garofalo C, Kanczuga-Koda L, Sulkowska M, Surmacz E (2003) Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors a and b. Horm Metab Res, 35: 794–801.
• 13. Koda M, Sulkowski S, Kanczuga-Koda L, Surmacz E, Sulkowska M (2004) Expression of ERa, ERb and Ki-67 in primary tumors and lymph node metastases in breast cancer. Oncol Rep, 11: 753–759.
• 14. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC (1995) Reduced expression of proapoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res, 55: 4471–4478.
• 15. Kumar R, Vadlamudi RK, Adam L (2000) Apoptosis in mammary gland and cancer. Endocr Relat Cancer, 7: 257–269.
• 16. Liu S, Edgerton SM, Moore DH 2nd, Thor AD (2001) Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res, 7: 1716–1723.
• 17. O’Reilly LA, Huang DC, Strasser A (1996) The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J, 15: 6979–6990.
• 18. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol, 124: 1–6.
• 19. Reed JC (1998) Bcl-2 family proteins. Oncogene, 17: 3225–3236.
• 20. Rochaix P, Krajewski S, Reed JC, Bonnet F, Voigt JJ, Brousset P (1999) In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol, 187: 410–415.
• 21. Sabourin JC, Martin A, Baruch J, Truc JB, Gompel A, Poitout P (1994) Bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer, 59: 1–6.
• 22. Schorr K, Li M, Krajewski S, Reed JC, Furth PA (1999) Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia, 4: 153–164.
• 23. Sierra A, Castellsague X, Coll T, Manas S, Escobedo A, Moreno A, Fabra A (1998) Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas. Int J Cancer, 79: 103–110.
• 24. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B (1996) P53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol, 14: 1604–1610.
• 25. Tavassoli FA, Devilee P (2003) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon.
• 26. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A (1998) Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res, 18: 1989–1998.